ArticleCost effectiveness and resource allocation : C/E2025

Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China.

Shixian Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.